Study to Assess Safety & Tolerability of AZD2281 in Combination With Bevacizumab in Patients With Advanced Solid Tumours
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
Phase I, open label, dual centre, dose finding study to evaluate the safety and tolerability
of continuous twice daily oral dosing with AZD2281 when administered in combination with
Bevacizumab 10mg/kg given every 2 weeks to patients with advanced solid tumours.